Iron Deficiency Anemia Market

DelveInsight’s Iron Deficiency Anemia Market Report provides a comprehensive understanding of Iron Deficiency Anemia, historical and forecasted epidemiology, and Iron Deficiency Anemia market patterns in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan).

Some of the Key Highlights from the Iron Deficiency Anemia Market Report

• According to the World Health Organization (WHO), 42 percent of children under the age of five are anemic.

• As per DelveInsight’s Iron Deficiency Anemia epidemiology insights, the total prevalent population was over 30 million in the 7MM out of which Japan accounted for the highest number of Iron Deficiency Anemia prevalent cases in 2020.

• As per the DelveInsight analysis, Iron Deficiency Anemia affects females more than males.

• Several pharma giants such as MegaPro Biomedical, Nemysis, Rockwell Medical, and others are thoroughly working toward the development of new treatment therapies for Iron Deficiency Anemia, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with IDA.

• MegaPro Biomedical’s MPB-1514/ IOP Injection is a non-sugar iron injection being developed for Iron Deficiency Anemia treatment.

• Aside from that, Nemysis is working on IHAT-02/IDAX, a novel oral iron formulation that is the first natural ferritin mimic, in which a tartrate salt is used to “dope” the ferrihydrite nanocore of ferritin in an adipate buffer.

For a better understanding of the disease, request for sample @ Iron Deficiency Anemia Treatment Market

The Iron Deficiency Anemia market report covers current clinical practices, new medications, Iron Deficiency Anemia market share of individual therapies, current and forecasted Iron Deficiency Anemia market Size from 2018 to 2030 segmented by seven major markets.

Iron Deficiency Anemia: Overview

Iron Deficiency Anemia (IDA) is the most common type of anemia worldwide, accounting for roughly half of all anemia. IDA is a condition in which the body’s iron stores are depleted, resulting in a drop in RBCs. Iron is required for the formation of RBCs, which aid the body in the storage and transportation of oxygen. If the body has fewer RBCs than normal, the organs and tissues do not receive as much oxygen as they should.

Iron Deficiency Anemia Epidemiology Segmentation

The Iron Deficiency Anemia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Iron Deficiency Anemia Total Prevalent Cases 

• Iron Deficiency Anemia Total Diagnosed Prevalent Cases

• Iron Deficiency Anemia Total Cases by Gender

• Iron Deficiency Anemia Total Cases by Pathology

• Iron Deficiency Anemia Severity-Specific Diagnosed Cases

• Iron Deficiency Anemia Total Treated Cases 

Iron Deficiency Anemia Treatment Landscape

The goal of Iron Deficiency Anemia treatment is to restore normal Hb levels and red cell indices, as well as to replenish iron reserves. Severe Iron Deficiency Anemia may require intravenous iron therapy (IV iron) or a blood transfusion. Some of the FDA-approved Intravenous (IV) drugs for Iron Deficiency Anemia treatment are Monofer, Feraheme, Injectafer, and Venofer. Apart from this, there are some FDA-approved oral drugs also such as Auryxia, Feraccru, and others that are used to treat Iron Deficiency Anemia.

Iron Deficiency Anemia Market

Key pharmaceutical companies such as Nemysis, MegaPro Biomedical, and others are expected to launch new therapies in the Iron Deficiency Anemia market.

The introduction of IHAT-02/IDAX, MPB-1514/ IOP Injection, and others are expected to give the Iron Deficiency Anemia market a significant boost in the forecast period 2021-30 in the 7MM.

Get a detailed analysis of the Iron Deficiency Anemia market @ Iron Deficiency Anemia Market Size

Iron Deficiency Anemia Pipeline Therapies and Key Companies 

• MPB-1514: MegaPro Biomedical

• IHAT-02/ IDAX: Nemysis

• Ferric pyrophosphate citrate (FPC): Rockwell Medical

Iron Deficiency Anemia Market Drivers

• Increasing changes in lifestyle

• Increasing cases of anemia

• Growth in geriatric population

 Iron Deficiency Anemia Market Barriers

• Extensive usage of over-the-counter (OTC) medications

• Availability of generics

• Lack of robust pipeline

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Iron Deficiency Anemia Key Companies: MegaPro Biomedical, Nemysis, Rockwell Medical, among others. 

Iron Deficiency Anemia Key Pipeline Therapies: IHAT-02/IDAX, MPB-1514/ IOP Injection, Ferric pyrophosphate citrate (FPC),and others.

Iron Deficiency Anemia Segmentation: By Geography, By Iron Deficiency Anemia therapies

Analysis: Comparative and conjoint analysis of Iron Deficiency Anemia emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents 

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Anemia in Elderly Market

Get comprehensive historical and forecast analysis of Anemia in Elderly Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as AMAG Pharmaceuticals, Vifor Pharma Inc., Rockwell Medical, Keryx Biopharmaceuticals Inc., Sanofi-Aventis U.S. LLC., Shield Therapeutics plc., Pharmacosmos A/S, American Regent/Vifor, Amgen Inc., Japan Tobacco, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/